Skip to main content
Fig. 7 | BMC Pulmonary Medicine

Fig. 7

From: Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy

Fig. 7

Exploration of the significance of risk-scores in clinical chemotherapy and immunotherapy response. A The expression of these risk genes (ARHGDIA, CDKN1A, and CCDC85B) remarkably increased in tumor patients using immunohistochemistry from HPA database. B the effective response rate of immunotherapy was significantly higher in the high-risk score group than in low-risk cohorts; C Difference of IC50 value between high- and low-risk groups for common chemotherapeutics drugs including Cisplatin, Docetaxel, Etoposide, Gemcitabine, and Vinorelbine

Back to article page